Arcellx, Inc. - Common Stock (NQ:ACLX)

115.00 +0.11 (+0.09%)

Streaming Delayed Price Updated: 12:11 PM EDT, Apr 15, 2026 Add to My Watchlist

Price and Volume

Volume	316,059
Open	114.89
Bid (Size)	114.99 (800)
Ask (Size)	115.00 (1,000)
Prev. Close	114.89
Today's Range	114.87 - 115.04
52wk Range	47.86 - 114.94
Shares Outstanding	48,358,981
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check

April 06, 2026

Gilead Sciences (NASDAQ: GILD) announced a strategic extension of its tender offer to acquire cell therapy innovator Arcellx (NASDAQ: ACLX) on April 1, 2026. Originally scheduled to expire on April 2,...

Via MarketMinute

Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution

March 31, 2026

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines...

Via MarketMinute

Performance

YTD	+81.6%	+81.6%
1 Month	+0.4%	+0.4%
3 Month	+72.3%	+72.3%
6 Month	+31.7%	+31.7%
1 Year	+90.7%	+90.7%

More News

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗

March 22, 2026

Via The Motley Fool

The Record-Breaking M&A Renaissance of 2026: Why Deal Values are Soaring as Volume Dips

March 19, 2026

Via MarketMinute

Halper Sadeh LLC is Investigating Whether KW, ACLX are Obtaining Fair Deals for their Shareholders

March 19, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether SEM, UNF, ACLX, FONR are Obtaining Fair Deals for their Shareholders

March 17, 2026

From Halper Sadeh LLC

Via GlobeNewswire

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally ↗

March 16, 2026

Via The Motley Fool

This Biotech Attracted a $181 Million Investment During a Staggering 1,300% Stock Rally ↗

March 16, 2026

Via The Motley Fool

This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal ↗

March 16, 2026

Via The Motley Fool

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

March 13, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Halper Sadeh LLC is Investigating Whether BCO, THR, ACLX are Obtaining Fair Deals for their Shareholders

March 05, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders

March 04, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement ↗

March 02, 2026

Via The Motley Fool

Arcellx President Sells $10M Worth of Shares After Acquisition Announcement ↗

March 02, 2026

Via The Motley Fool

Halper Sadeh LLC is Investigating Whether ACLX, EHAB, VRE are Obtaining Fair Deals for their Shareholders

February 24, 2026

From Halper Sadeh LLC

Via GlobeNewswire

Arcellx Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc. - ACLX

February 23, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Let's take a look at the stocks that are in motion in today's session. ↗

February 23, 2026

Via Chartmill

Here are the top movers in Monday's session. ↗

February 23, 2026

Via Chartmill

These stocks are gapping in today's session ↗

February 23, 2026

Via Chartmill

These stocks are moving in today's pre-market session ↗

February 23, 2026

Via Chartmill

ACLX Stock Alert: Halper Sadeh LLC is Investigating Whether Arcellx, Inc. is Obtaining a Fair Price for its Shareholders

February 23, 2026

From Halper Sadeh LLC

Via Business Wire

Why Did ACLX Stock Surge 80% In Pre-Market Today? ↗

February 23, 2026

Via Stocktwits

Gilead Sciences to Acquire Arcellx to Maximize Long-term Potential of Anito-cel

February 23, 2026

From Arcellx, Inc.

Via Business Wire

$80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗

February 22, 2026

Via The Motley Fool

Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗

February 17, 2026

Via The Motley Fool

Frequently Asked Questions

Is Arcellx, Inc. - Common Stock publicly traded?

Yes, Arcellx, Inc. - Common Stock is publicly traded.

What exchange does Arcellx, Inc. - Common Stock trade on?

Arcellx, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arcellx, Inc. - Common Stock?

The ticker symbol for Arcellx, Inc. - Common Stock is ACLX on the Nasdaq Stock Market

What is the current price of Arcellx, Inc. - Common Stock?

The current price of Arcellx, Inc. - Common Stock is 115.00

When was Arcellx, Inc. - Common Stock last traded?

The last trade of Arcellx, Inc. - Common Stock was at 04/15/26 12:11 PM ET

What is the market capitalization of Arcellx, Inc. - Common Stock?

The market capitalization of Arcellx, Inc. - Common Stock is 5.56B

How many shares of Arcellx, Inc. - Common Stock are outstanding?

Arcellx, Inc. - Common Stock has 6B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.